ArticleMicrobial cell factories2020
Engineering of a genome-reduced strain Bacillus amyloliquefaciens for enhancing surfactin production.
Article in Microbial cell factories, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Cas3-mediated genome reduction: demonstration in Cupriavidus necator H16 improves growth on heterotrophic and autotrophic carbon sources.Nucleic acids research · 2026Article
- Promoter Engineering of the Surfactin Operon Enhances Surfactin Production in the Environmental Strain Bacillus subtilis RI4914.Current microbiology · 2026Article
- Molecular mechanisms in endometriosis: linking JAK/STAT pathway, ferroptosis, and microbial dysbiosis.Molecular biology reports · 2026Review
- Review
- Antifungal Biocontrol in Sustainable Crop Protection: Microbial Lipopeptides, Polyketides, and Plant-Derived Agents.Journal of fungi (Basel, Switzerland) · 2025Review
- Integrated Biofilm Modification and Transcriptional Analysis for Improving Fengycin Production in Bacillus amyloliquefaciens.Probiotics and antimicrobial proteins · 2025Article
- Application of Combined Irradiation Mutagenesis Technique for Hyperproduction of Surfactin inInternational journal of microbiology · 2025Article
- Broad-Spectrum Virus Elimination by Nasal Mucosa-Colonized Wild-TypeResearch (Washington, D.C.) · 2025Article
- In Vitro Antagonistic Activity of Plant Growth Promoting Rhizobacteria Against Aggressive Biotypes of the Green Mold.Journal of basic microbiology · 2024Article
- Elucidating the salt-tolerant mechanism of Halomonas cupida J9 and unsterile ectoine production from lignocellulosic biomass.Microbial cell factories · 2024Article
- Application of Biosurfactants in Medical Sciences.Molecules (Basel, Switzerland) · 2024Review
- Strategies for improving fengycin production: a review.Microbial cell factories · 2024Review
- Recent advances in the characterization of essential genes and development of a database of essential genes.iMeta · 2024Review
- Bioactivity and genome analysis of Bacillus amyloliquefaciens GL18 isolated from the rhizosphere of Kobresia myosuroides in an alpine meadow.Antonie van Leeuwenhoek · 2024Article
- Genome reduction inFrontiers in bioengineering and biotechnology · 2024Article
- Promising non-model microbial cell factories obtained by genome reduction.Frontiers in bioengineering and biotechnology · 2024Review
- Unlocking the potential of biosurfactants: Innovations in metabolic and genetic engineering for sustainable industrial and environmental solutions.Biotechnology notes (Amsterdam, Netherlands) · 2024Review
- Antimicrobial peptides from Bacillus spp. and strategies to enhance their yield.Applied microbiology and biotechnology · 2023Review
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundGenome reduction and metabolic engineering have emerged as intensive research hotspots for constructing the promising functional chassis and various microbial cell factories. Surfactin, a lipopeptide-type biosurfactant with broad spectrum antibiotic activity, has wide application prospects in anticancer therapy, biocontrol and bioremediation. Bacillus amyloliquefaciens LL3, previously isolated by our lab, contains an intact srfA operon in the genome for surfactin biosynthesis.
resultsIn this study, a genome-reduced strain GR167 lacking ~ 4.18% of the B. amyloliquefaciens LL3 genome was constructed by deleting some unnecessary genomic regions. Compared with the strain NK-1 (LL3 derivative, ΔuppΔpMC1), GR167 exhibited faster growth rate, higher transformation efficiency, increased intracellular reducing power level and higher heterologous protein expression capacity. Furthermore, the chassis strain GR167 was engineered for enhanced surfactin production. Firstly, the iturin and fengycin biosynthetic gene clusters were deleted from GR167 to generate GR167ID. Subsequently, two promoters PR
conclusionsThe genome-reduced strain GR167 was advantageous over the parental strain in several industrially relevant physiological traits assessed and it was highlighted as a chassis strain for further genetic modification. In future studies, further reduction of the LL3 genome can be expected to create high-performance chassis for synthetic biology applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.